7 recruiting, 3 not yet recruiting, 2 active not recruiting, 1 terminated. 3 Phase 3, 2 Phase 4, 1 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Recruiting 2, Active not recruiting 1 |
| Phase 4 | 2 | Recruiting 1, Terminated 1 |
| Early Phase 1 | 1 | Recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
Follow NMOSD: new trials by email Literature Review of NMOSD trials Research Report on NMOSD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD Rituximab (R), Eculizumab (Soliris®), Ravulizumab - NMOSD | Phase 4 | Recruiting | Massachusetts General Hospital | 540 | 2026-09-01 | 2026-09-24 |
| Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD) Ravulizumab - NMOSD, Neuromyelitis Optica Spectrum Disorder | Phase 3 | Recruiting | Alexion Pharmaceuticals, Inc. | 19 | 2026-07-20 | 2026-09-11 |
| A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) Satralizumab - Neuromyelitis Optica Spectrum Disorder, NMOSD | Phase 3 | Recruiting | Hoffmann-La Roche | 8 | 2026-05-06 | 2026-10-01 |
| Prospective Cohort Study of Neuromyelitis Optica Spectrum Disorders (NMOSD) Sex hormone assay - NMOSD | Not yet recruiting | Xiamen Hospital of Traditional Chinese Medicine | 4000 | 2025-12-01 | 2025-12-18 | |
| Efficacy and Safety of Monoclonal Antibody in Acute Phase of Neuromyelitis Optica Spectrum Disorder NMOSD | Not yet recruiting | First Affiliated Hospital of Chongqing Medical University | 40 | 2025-10-01 | 2025-09-19 | |
| Clinical Study to Evaluate the Effects of the Complement C5 Inhibitor Ravulizumab on Serum Neurofilament Light Chain (sNfL) and Glial Fibrillary Acidic Protein (sGFAP) Levels in Patients With Aquaporin-4-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Blood samples for sNfL and sGFAP levels - NMOSD | Not yet recruiting | National and Kapodistrian University of Athens | 40 | 2025-09-01 | 2025-07-01 | |
| Assessment of Transcranial Alternating Current Stimulation's Clinical Efficacy in Treating Cognitive Impairment of Idiopathic Inflammatory Demyelinating Diseases Neuroelectrical modulation group, Pseudo-neuromodulation group - Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System, MS (Multiple Sclerosis) | Not applicable | Recruiting | Xuanwu Hospital, Beijing | 128 | 2025-05-30 | 2025-07-28 |
| Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD eculizumab - NMOSD, Neuromyelitis Optica Spectrum Disorders | Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 21 | 2025-01-16 | 2025-12-19 |
| Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases RD06-05 CART Cell Injection - SLE, Systemic Sclerosis | Early Phase 1 | Recruiting | Nanjing Bioheng Biotech Co., Ltd. | 18 | 2025-01-03 | 2026-02-02 |
| Comparative Study on AQP4 Antibody Detection Methods NMOSD | Active not recruiting | First Affiliated Hospital of Chongqing Medical University | 120 | 2023-11-11 | 2025-01-09 | |
| Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies Neuromyelitis Optica Spectrum Disorder, NMOSD | Recruiting | Alexion Pharmaceuticals, Inc. | 200 | 2023-08-30 | 2026-10-13 | |
| A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention Satralizumab 120 mg - Neuromyelitis Optica Spectrum Disorder, NMOSD | Phase 4 | Terminated | Hoffmann-La Roche | 4 | 2022-08-02 | 2025-01-22 |
| Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA) Multiple Sclerosis, Clinically Isolated Syndrome | Recruiting | University of California, San Francisco | 250 | 2017-03-21 | 2026-08-11 |
Neuromyelitis Optica (5) · Multiple Sclerosis (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Encephalomyelitis, Acute Disseminated (1) · Myasthenia Gravis (1) · Scleroderma, Systemic (1)
Autoimmune Diseases (8) · Immune System Diseases (8) · Autoimmune Diseases of the Nervous System (7) · Demyelinating Autoimmune Diseases, CNS (7) · Demyelinating Diseases (7) · Nervous System Diseases (7) · Cranial Nerve Diseases (5) · Eye Diseases (5) · Myelitis, Transverse (5) · Optic Nerve Diseases (5) · Optic Neuritis (5) · Brain Diseases (1) · Cardiovascular Diseases (1) · Central Nervous System Diseases (1) · Chronic Disease (1)
satralizumab (3) · eculizumab (2) · ravulizumab (2) · Blood Specimen Collection (1) · Rituximab (1) · inebilizumab (1)
Alexion Pharmaceuticals, Inc. (3) · First Affiliated Hospital of Chongqing Medical University (2) · Hoffmann-La Roche (2) · Massachusetts General Hospital (1) · Nanjing Bioheng Biotech Co., Ltd. (1) · National and Kapodistrian University of Athens (1) · University of California, San Francisco (1) · Xiamen Hospital of Traditional Chinese Medicine (1) · Xuanwu Hospital, Beijing (1)
China (8) · United States (5) · Argentina (2) · Germany (2) · Italy (2) · South Korea (2) · Turkey (Türkiye) (2) · Canada (1) · France (1) · Greece (1) · Japan (1) · Mexico (1) · Poland (1) · United Kingdom (1)
Jinzhou Feng, Ph.D (2) · Pablo Lopez (1) · Philippe-Antoine Bilodeau, MD (1) · Riley Bove, MD, MSc (1) · Shiyong Li (1) · Xiangjun Chen, M.D (1)
2019 (1), 2023 (1)